JP7737098B2 - 感染性疾患、自己免疫疾患、およびアレルギー性疾患を治療するための方法および組成物 - Google Patents

感染性疾患、自己免疫疾患、およびアレルギー性疾患を治療するための方法および組成物

Info

Publication number
JP7737098B2
JP7737098B2 JP2021524290A JP2021524290A JP7737098B2 JP 7737098 B2 JP7737098 B2 JP 7737098B2 JP 2021524290 A JP2021524290 A JP 2021524290A JP 2021524290 A JP2021524290 A JP 2021524290A JP 7737098 B2 JP7737098 B2 JP 7737098B2
Authority
JP
Japan
Prior art keywords
cacae
mice
prebiotic
cma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510780A (ja
JP2022510780A5 (cg-RX-API-DMAC7.html
Inventor
キャスリン アール． ナグラー
リーユエ バオ
ディオニシオス アントノポウロス
ジョン ダブリュ． コルソン
ローレン アンダース ヘッサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2022510780A publication Critical patent/JP2022510780A/ja
Publication of JP2022510780A5 publication Critical patent/JP2022510780A5/ja
Application granted granted Critical
Publication of JP7737098B2 publication Critical patent/JP7737098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
JP2021524290A 2018-11-05 2019-11-05 感染性疾患、自己免疫疾患、およびアレルギー性疾患を治療するための方法および組成物 Active JP7737098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755945P 2018-11-05 2018-11-05
US62/755,945 2018-11-05
PCT/US2019/059865 WO2020097077A1 (en) 2018-11-05 2019-11-05 Methods and compositions for treating infectious, autoimmune, and allergic disease

Publications (3)

Publication Number Publication Date
JP2022510780A JP2022510780A (ja) 2022-01-28
JP2022510780A5 JP2022510780A5 (cg-RX-API-DMAC7.html) 2022-11-10
JP7737098B2 true JP7737098B2 (ja) 2025-09-10

Family

ID=70611079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524290A Active JP7737098B2 (ja) 2018-11-05 2019-11-05 感染性疾患、自己免疫疾患、およびアレルギー性疾患を治療するための方法および組成物

Country Status (9)

Country Link
US (1) US12589122B2 (cg-RX-API-DMAC7.html)
EP (1) EP3876755A4 (cg-RX-API-DMAC7.html)
JP (1) JP7737098B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210098464A (cg-RX-API-DMAC7.html)
CN (1) CN113271796A (cg-RX-API-DMAC7.html)
AU (1) AU2019374773B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008767A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118679A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020097077A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271796A (zh) 2018-11-05 2021-08-17 芝加哥大学 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物
WO2022020852A1 (en) * 2020-07-22 2022-01-27 The University Of Chicago Methods and compositions for treating autoimmune and allergic disorders
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease
JP7124148B1 (ja) * 2021-03-08 2022-08-23 Ｖａｒｉｎｏｓ株式会社 微生物叢のメタゲノム解析
EP4426354A4 (en) * 2021-11-03 2025-10-08 Univ Chicago PRODRUG COPOLYMERS AND POLYMERIC MICELLES THEREOF FOR DELIVERY OF SHORT-CHAIN FATTY ACIDS, PROMOTION OF GUT HEALTH, AND TREATMENT OF IMMUNE AND/OR INFLAMMATORY CONDITIONS AND FOOD ALLERGY
WO2025183115A1 (ja) * 2024-02-28 2025-09-04 三菱ケミカル株式会社 乳酸産生菌及び酪酸産生菌を含む整腸用組成物
CN120843703A (zh) * 2025-07-24 2025-10-28 上海市生物医药技术研究院 一种利用癌组织的特定微生物预测乳腺癌原位复发的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
WO2018057914A1 (en) 2016-09-22 2018-03-29 The University Of Chicago Immune response modulation using live biotherapeutics, for conditions such as allergy desensitization
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
JP2019511563A (ja) 2016-02-04 2019-04-25 ユニベルシテイト ゲントＵｎｉｖｅｒｓｉｔｅｉｔ Ｇｅｎｔ ヒトおよび動物の健康ための微生物コミュニティーの使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
US20140161878A1 (en) * 2012-12-12 2014-06-12 Sweet Wellness AB Multi-nutrient supplement and uses thereof
US9956282B2 (en) * 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6754694B2 (ja) 2014-03-06 2020-09-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル プロバイオティクス製剤および使用のための方法
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016149687A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
CN115252650A (zh) 2015-11-03 2022-11-01 布里格姆及妇女医院股份有限公司 用于治疗和/或预防食物变态反应的治疗性微生物群
WO2018075886A1 (en) 2016-10-21 2018-04-26 The University Of Chicago Compositions and methods for inducing immune system maintenance to prevent and/or treat infections
CA3045026A1 (en) 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
WO2018107365A1 (zh) * 2016-12-13 2018-06-21 深圳华大基因研究院 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
WO2018129249A1 (en) 2017-01-05 2018-07-12 The University Of Chicago Inhibition of enteric infection through the modulation of microbiota
EP3606325B1 (en) * 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
CN113271796A (zh) 2018-11-05 2021-08-17 芝加哥大学 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物
ES2763874B2 (es) 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2019511563A (ja) 2016-02-04 2019-04-25 ユニベルシテイト ゲントＵｎｉｖｅｒｓｉｔｅｉｔ Ｇｅｎｔ ヒトおよび動物の健康ための微生物コミュニティーの使用
WO2018057914A1 (en) 2016-09-22 2018-03-29 The University Of Chicago Immune response modulation using live biotherapeutics, for conditions such as allergy desensitization
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Alvaro BELENGUER et al.，"Two Routes of Metabolic Cross-Feeding between Bifidobacterium adolescentis and Butyrate-Producing Anaerobes from the Human Gut"，Applied and Environmental Microbiology，2006年05月，Vol. 72, No. 5，p.3593-3599，DOI: 10.1128/AEM.72.5.3593-3599.2006
Tadashi Saito，Isolation of lacto-utilizing butylate-producing bacteria from human feces and in vivo administration of Anaerostipes caccae strain L2 and galacto-oligosaccharides ina rat model，FEMS Microbiol Ecol，2008年，66，528-536

Also Published As

Publication number Publication date
WO2020097077A1 (en) 2020-05-14
JP2022510780A (ja) 2022-01-28
EP3876755A4 (en) 2022-08-24
CN113271796A (zh) 2021-08-17
BR112021008767A2 (pt) 2021-08-17
US20210386796A1 (en) 2021-12-16
KR20210098464A (ko) 2021-08-10
AU2019374773A1 (en) 2021-06-10
US12589122B2 (en) 2026-03-31
EP3876755A1 (en) 2021-09-15
CA3118679A1 (en) 2020-05-14
AU2019374773B2 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
JP7737098B2 (ja) 感染性疾患、自己免疫疾患、およびアレルギー性疾患を治療するための方法および組成物
US11672834B2 (en) Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
Quinn et al. Environmental determinants of type 1 diabetes: from association to proving causality
JP6868562B2 (ja) 障害の微生物的処置および診断に関する方法および組成物
ES3017865T3 (en) Synergistic bacterial compositions and methods of production and use thereof
EP3978598A1 (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
Walker et al. Atopy and the gastrointestinal tract–a review of a common association in unexplained gastrointestinal disease
CA2983016A1 (en) Microbiome regulators and related uses thereof
Khuat et al. The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
US20230256034A1 (en) Methods and compositions for treating autoimmune and allergic disorders
El Morr Les cellules MAIT et la riboflavine dans les interactions hôte-microbiote
HK40070967A (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
Ceylan Holistic Review of the Association Between Microbiome and Immune-Mediated Inflammatory Diseases
HK1244683B (en) Probiotic and prebiotic compositions comprising blautia species for reducing inflammation
Di Paola The Birth of hologenome: how diet, genes and environment shape the bacterial and fungal gut communities in children

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221101

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250820

R150 Certificate of patent or registration of utility model

Ref document number: 7737098

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150